-Advertisement-
-Advertisement-
FDA Alerts
FDA approves Tecvayli for previously treated relapsed/refractory multiple myeloma
The U.S. Food and Drug Administration has approved teclistamab-cqyv (Tecvayli) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received ≥4 prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate....
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Contact
© 2024 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved